Hladunewich Michelle A, Hou Susan, Odutayo Ayodele, Cornelis Tom, Pierratos Andreas, Goldstein Marc, Tennankore Karthik, Keunen Johannes, Hui Dini, Chan Christopher T
Department of Medicine, Division of Nephrology, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, Ontario, Canada; Department of Medicine, Division of Nephrology, University Health Network, University of Toronto, Toronto, Ontario, Canada;
Department of Medicine, Division of Nephrology, Loyola University Medical Center, Maywood Illinois;
J Am Soc Nephrol. 2014 May;25(5):1103-9. doi: 10.1681/ASN.2013080825. Epub 2014 Feb 13.
Pregnancy is rare in women with ESRD and when it occurs, it is often accompanied by significant maternal and fetal morbidity and even mortality. Preliminary data from the Toronto Nocturnal Hemodialysis Program suggested that increased clearance of uremic toxins by intensified hemodialysis improves pregnancy outcomes, but small numbers and the absence of a comparator group limited widespread applicability of these findings. We compared pregnancy outcomes from 22 pregnancies in the Toronto Pregnancy and Kidney Disease Clinic and Registry (2000-2013) with outcomes from 70 pregnancies in the American Registry for Pregnancy in Dialysis Patients (1990-2011). The primary outcome was the live birth rate and secondary outcomes included gestational age and birth weight. The live birth rate in the Canadian cohort (86.4%) was significantly higher than the rate in the American cohort (61.4%; P=0.03). Among patients with established ESRD, the median duration of pregnancy in the more intensively dialyzed Toronto cohort was 36 weeks (interquartile range, 32-37) compared with 27 weeks (interquartile range, 21-35) in the American cohort (P=0.002). Furthermore, a dose response between dialysis intensity and pregnancy outcomes emerged, with live birth rates of 48% in women dialyzed ≤20 hours per week and 85% in women dialyzed >36 hours per week (P=0.02), with a longer gestational age and greater infant birth weight for women dialyzed more intensively. Pregnancy complications were few and manageable. We conclude that pregnancy may be safe and feasible in women with ESRD receiving intensive hemodialysis.
终末期肾病(ESRD)女性怀孕的情况较为罕见,一旦发生,往往伴随着严重的母婴发病甚至死亡。多伦多夜间血液透析项目的初步数据表明,强化血液透析增加尿毒症毒素清除可改善妊娠结局,但样本量小且缺乏对照组限制了这些发现的广泛应用。我们将多伦多妊娠与肾病诊所及登记处(2000 - 2013年)22例妊娠的结局与美国透析患者妊娠登记处(1990 - 2011年)70例妊娠的结局进行了比较。主要结局是活产率,次要结局包括孕周和出生体重。加拿大队列的活产率(86.4%)显著高于美国队列(61.4%;P = 0.03)。在已确诊ESRD的患者中,血液透析更强化的多伦多队列的妊娠中位持续时间为36周(四分位间距,32 - 37周),而美国队列为27周(四分位间距,21 - 35周)(P = 0.002)。此外,透析强度与妊娠结局之间呈现剂量反应关系,每周透析≤20小时的女性活产率为48%,每周透析>36小时的女性活产率为85%(P = 0.02),透析更强化的女性孕周更长,婴儿出生体重更大。妊娠并发症较少且可控。我们得出结论,接受强化血液透析的ESRD女性怀孕可能是安全可行的。